| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 343.39% | £310,371.65 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 249.91% | £244,939.23 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 168.72% | £188,106.38 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | 162.84% | £183,987.91 | |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 43.37% | £100,360.37 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 33.07% | £93,147.36 |
| Lord Mance |
|
Stryker / NYQ:SYK | 11.93% | £78,349.09 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 7.16% | £75,009.39 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -18.76% | £56,870.98 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -21.27% | £55,113.62 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -33.49% | £46,559.27 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |